July 9, 2020

Trianni, Zoetis announce agreement to develop transgenic antibody discovery platform for use in animal health

Trianni, Inc. and Zoetis have announced on July 7 a collaboration for the development of transgenic monoclonal antibody platforms for the discovery of new veterinary treatments.

"We are confident that the application of Trianni's proven transgenic human monoclonal antibody discovery platform technology to the veterinary field will add value to Zoetis' product development programmes," said Matthias Wabl, Trianni's president and CEO.

"We appreciate TRIANNI's experience in the development of therapeutic antibody platform capabilities and look forward to working with them on innovations for animal health," said Catherine A. Knupp, executive vice president and president of research and development at Zoetis. "This collaboration will enhance our internally-developed pipeline of novel monoclonal antibodies and hasten the development of therapeutics that could transform the way veterinarians treat a range of diseases in animals."

No financial details were disclosed.

- Zoetis